TP53 and endometrial cancer: Additionally, while research indicates that WEE1 inhibitors show synthetic lethality in P53 mutant tumors35, and TP53 mutation is associated with a worse prognosis in endometrial cancer, we observed that AZD1775 exhibited strong cytotoxic effects in P53 mutant endometrial cancer.